share_log

Arcutis Biotherapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Watanabe Todd Franklin

SEC announcement ·  May 4 04:29
Summary by Futu AI
Todd Franklin Watanabe, associated with Arcutis Biotherapeutics, completed a sale of 13,783 shares of common stock on May 2, 2024. The transaction was executed at a price of $8.7378 per share, resulting in a total sale value of approximately $120,433. Following the sale, Watanabe directly holds 860,750 shares of the company. The sale took place in the open market and was part of a planned disposition of shares. Additionally, Watanabe has indirect beneficial ownership of 231,140 shares through trusts and an LLC.
Todd Franklin Watanabe, associated with Arcutis Biotherapeutics, completed a sale of 13,783 shares of common stock on May 2, 2024. The transaction was executed at a price of $8.7378 per share, resulting in a total sale value of approximately $120,433. Following the sale, Watanabe directly holds 860,750 shares of the company. The sale took place in the open market and was part of a planned disposition of shares. Additionally, Watanabe has indirect beneficial ownership of 231,140 shares through trusts and an LLC.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.